• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·COAG
Held by 1 Guru
Share

Hemab Therapeutics Holdings, Inc. Stocks

$ 43.1Last Updated 03.11.2026

Issuer Rating

3/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 1.92B

$ 43.1
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

03.05.2026 21:00

S&P goes after SpaceX, Uzbekistan fund to offer discount: the main thing about the IPO by Ma. 3

01.05.2026 15:00

Hemab IPO: Novo-backed blood disorder biotech debuts on the Nasdaq

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of COAG is 60.1 and suggests 40.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.11.2026 04:39

The SpaceX contract didn't help Qualcomm: Investors were disappointed by the earnings forecast

05.11.2026 02:14

The Dow soared 3% following the Democrats' election victory: this is its best gain in 1.5 years

05.11.2026 01:29

Five tech giants gain $750 bln post-midterms. JPMorgan sees the rally broadening.

05.11.2026 00:54

Shares of defense companies fell following the Democrats' success in the U.S. What happens next?

05.11.2026 00:02

Brent crude falls 10% as Democratic sweep raises hopes for end to Iran war

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026